Recombinant Marburg virus NP(Popp/1967) [His]

Name: Recombinant Marburg virus NP(Popp/1967) [His]
SKU: DAGA-3115
Rating: 5 (1 reviews)

Marburg virus (Popp/1967) nucleoprotein, recombinant from E. coli

COA

SDS

Datasheet

Summary

Target

Marburg virus NP

Tag/Conjugate

His

Molecular Weight

82 kDa

Purity

> 90% as determined by SDS-PAGE

Format

Liquid

Buffer

50mM Tris-HCl, 200mM NaCl, pH8.0

Preservative

None

Storage

Store at -20°C or below. Avoid multiple freeze/thaw cycles.

Introduction

Encapsidates the genome, protecting it from nucleases. The encapsidated genomic RNA is termed the nucleocapsid and serves as template for transcription and replication. During replication, encapsidation by NP is coupled to RNA synthesis and all replicative products are resistant to nucleases.

Keywords

Marburg virus; Nucleoprotein; NP

Citations

Have you cited DAGA-3115 in a publication? Let us know and earn a reward for your research.

Longitudinal proteome-wide antibody profiling in Marburg virus survivors identifies wing domain immunogen for vaccine design

Khurana S, Grubbs G, Ravichandran S, Cluff E, Kim J, Kuehne AI, Zak S, Dye JM, Lutwama JJ, Herbert AS

Nat Commun2024 SepPubMed ID: 39285186Read Article

Applications: SPR

Reactive species: Human

"Abstract: Limited knowledge exists on the quality of polyclonal antibody responses generated following Marburg virus (MARV) infection and its evolution in survivors. In this study, we evaluate MARV proteome-wide antibody repertoire longitudinally in convalescent phase approximately every six months for five years following MARV infection in ten human survivors. Differential kinetics were observed for IgM vs IgG vs IgA epitope diversity, antibody binding, antibody affinity maturation and Fc-receptor interaction to MARV proteins. Durability of MARV-neutralizing antibodies is low in survivors. MARV infection induces a diverse epitope repertoire with predominance against GP, VP40, VP30 and VP24 that persisted up to 5 years post-exposure. However, the IgM and IgA repertoire declines over time. Within MARV-GP, IgG recognize antigenic sites predominantly in the amino-terminus, wing domain and GP2-heptad repeat. Interestingly, MARV infection generates robust durable FcɣRI, FcɣRIIA and FcɣRIIIA IgG-Fc receptor interactions. Immunization with immunodominant MARV epitopes reveals conserved wing region between GP1 and GP2, induces neutralizing antibodies against MARV. These findings demonstrate that MARV infection generates a diverse, long-lasting, non-neutralizing, IgG antibody repertoire that perturbs disease by FcɣR activity. This information, along with discovery of neutralizing immunogen in wing domain, could aid in development of effective therapeutics and vaccines against Marburg virus."

Article snippet: Recombinant Marburg virus-like particles (VLPs expressing MARV trimeric GP on surface of particles made of MARV matrix proteins VP40 and NP), and MARV GP, NP, VP35, VP40, VP24, VP30 and L polymerase proteins were purchased from *, *, and Creative Diagnostics Inc.